The use of frailty assessments in treating older adults with aggressive lymphomas

Raul Cordoba, Stefano Luminari, Toby A. Eyre

Research output: Contribution to journalReview articlepeer-review


Non-Hodgkin lymphomas (NHL) are most commonly diagnosed among people aged 65–74 years, with a median age at diagnosis of 67 years. The percentage of NHL-related deaths is highest among people aged 75–84 years, with a median age at death of 76 years from cases between 2014 and 2018. In light of these recent data, attending physicians of patients with NHL will recognize that the majority of their patients will be of advanced age, with many suffering from a spectrum of frailties. The excess rate of death among older adults with NHL may be related to a range of different factors such as more challenging biologic features, undertreatment received due to a patient’s chronology and treatment-related toxicity. The aim of this review is to provide an updated overview of the knowledge generated over recent years regarding epidemiology, prognosis and treatment options in older adults with lymphoma, focusing on Diffuse Large B-cell Lymphoma (DLBCL) where the most robust evidence base is available.

Original languageEnglish
Pages (from-to)677-685
Number of pages9
JournalBritish Journal of Haematology
Issue number4
Publication statusPublished - Aug 2021


  • elderly
  • frailty
  • geriatric hematology
  • lymphomas
  • non-Hodgkin-S lymphoma

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'The use of frailty assessments in treating older adults with aggressive lymphomas'. Together they form a unique fingerprint.

Cite this